Xbiotech INC Form 4 insider transactions

Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.

NASDAQ
XBiotech Inc. Director Craig Rademaker received 92,104 stock options at an exercise price of $2.64, vesting over ten months.
NASDAQ
XBiotech Inc. Director David Spencer Soffer was granted 51,000 nonstatutory stock options at an exercise price of $2.64, vesting over ten months.
NASDAQ
XBiotech Inc. director Thomas Kuendig was granted 79,115 nonstatutory stock options with an exercise price of $2.64, vesting in two tranches.
NASDAQ
XBiotech Inc. Director Tevi Troy received a grant of 56,000 nonstatutory stock options with an exercise price of $2.64, vesting in two tranches.
NASDAQ
John Simard, CEO of XBiotech Inc., was granted stock options for 1,026,228 shares of common stock on March 17, 2025.
NASDAQ
John Simard, CEO of XBiotech, terminated a convertible loan agreement with the company following full repayment, extinguishing all associated stock conversion rights.
NASDAQ
Director W. Thorpe McKenzie was granted nonstatutory stock options to purchase 37,500 shares of XBiotech Inc.'s common stock on June 20, 2024.
NASDAQ
Director Jan-Paul Waldin of XBiotech Inc. was granted nonstatutory stock options to purchase 37,500 shares of common stock on June 20, 2024.
NASDAQ
Director Donald H. MacAdam was granted stock options to purchase 37,500 shares of XBiotech Inc. common stock on June 20, 2024.
NASDAQ
Director Peter Libby was granted stock options to purchase 37,500 shares of XBiotech Inc. common stock on June 20, 2024.